Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on August 24, 2018, covering events occurring on August 21, 2018. The Company is a Delaware corporation focused on medical technologies, specifically the HemoDefend red blood cell (RBC) transfusion filter.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is the value of a new grant award.
Material Changes
The primary material event is the award of a three-year Phase IIB Bridge SBIR (Small Business Innovation Research) grant by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). The award is valued at up to $3 million and is intended to facilitate and accelerate the commercialization of the Company's HemoDefend RBC transfusion filter.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the grant. The filing does not provide updated financial guidance, specific risk factors, or contingencies beyond the standard nature of SBIR awards. The grant supports the commercialization phase of a specific product line.
Investor Verification Checklist
- Verify the terms and milestones associated with the $3 million NHLBI SBIR award.
- Review the full text of the press release filed as Exhibit 99.1 for details on the HemoDefend filter's development status.
- Confirm the impact of this non-dilutive funding on the Company's overall cash runway and burn rate.
- Check subsequent filings for any updates on the commercialization timeline for HemoDefend.